

# CITATION REPORT

List of articles citing

**On the role of coagulation and fibrinolysis in atherosclerosis**

**DOI: 10.1016/1047-2797(92)90092-5**  
**Annals of Epidemiology, 1992, 2, 427-38.**

**Source:** <https://exaly.com/paper-pdf/23257635/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
65	Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis. <i>Metabolism: Clinical and Experimental</i> , <b>1992</b> , 41, 2-6	12.7	17
64	Biological effects of inactivation of the genes for tissue-type plasminogen activator, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in mice. <i>Fibrinolysis</i> , <b>1993</b> , 7, 27-28		2
63	Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , <b>1994</b> , 14, 1730-6		80
62	Physiological consequences of loss of plasminogen activator gene function in mice. <i>Nature</i> , <b>1994</b> , 368, 419-24	50.4	954
61	Transgenic animals as tools for the study of fibrinolysis in vivo. <i>Journal of Internal Medicine</i> , <b>1994</b> , 236, 455-9	10.8	6
60	Evaluation of the plasminogen/plasmin system in transgenic mice. <i>Fibrinolysis</i> , <b>1994</b> , 8, 269-276		30
59	The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. <i>Fibrinolysis</i> , <b>1994</b> , 8, 294-303		40
58	Physiology and pathophysiology of the fibrinolytic system. <i>Fibrinolysis</i> , <b>1995</b> , 9, 3-8		20
57	Lipids, risk factors and ischaemic heart disease. <i>Atherosclerosis</i> , <b>1996</b> , 124 Suppl, S1-9	3.1	255
56	Genetic analysis of the plasminogen and coagulation system in mice. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1996</b> , 26 Suppl 4, 132-53		3
55	Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice. <i>Fibrinolysis</i> , <b>1996</b> , 10, 195-213		33
54	Who Should Receive Hormone Replacement Therapy?. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1996</b> , 3, 13-21	5.1	6
53	Effects of hyperthermal stress on the fibrinolytic system. <i>International Journal of Hyperthermia</i> , <b>1996</b> , 12, 31-6	3.7	17
52	Gene manipulation and transfer of the plasminogen and coagulation system in mice. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1996</b> , 22, 525-42	5.3	45
51	Insights from gene-inactivation studies of the coagulation and plasminogen. <i>Fibrinolysis and Proteolysis</i> , <b>1997</b> , 11, 181-191		5
50	Molecular analysis of blood vessel formation and disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>1997</b> , 273, H2091-104	5.2	55
49	Effects of garlic on atherosclerosis. <i>Nutrition</i> , <b>1997</b> , 13, 656-63	4.8	62

48	Moderate beer consumption and the blood coagulation in patients with coronary artery disease. <i>Journal of Internal Medicine</i> , <b>1997</b> , 241, 47-51	10.8	67
47	Vascular development and disorders: molecular analysis and pathogenic insights. <i>Kidney International</i> , <b>1998</b> , 53, 1519-49	9.9	84
46	Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. <i>Thrombosis Research</i> , <b>1998</b> , 91, 255-85	8.2	160
45	Pregnancy-induced hypertension and insulin resistance, evidence for a connection. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>1999</b> , 78, 263-284	3.8	52
44	Pregnancy-induced hypertension and insulin resistance, evidence for a connection. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>1999</b> , 78, 263-284	3.8	11
43	Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. <i>American Journal of Obstetrics and Gynecology</i> , <b>1999</b> , 180, S349-56	6.4	30
42	Antithrombotics. <i>Handbook of Experimental Pharmacology</i> , <b>1999</b> ,	3.2	2
41	New Developments in the Molecular Biology of Coagulation and Fibrinolysis. <i>Handbook of Experimental Pharmacology</i> , <b>1999</b> , 41-76	3.2	1
40	Transgenic mouse models in angiogenesis and cardiovascular disease. <i>Journal of Pathology</i> , <b>2000</b> , 190, 387-405	9.4	97
39	Key references: Basic fibrinolysis and thrombolysis selected references: 1987-1997. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2000</b> , 9, 61-8	5.1	
38	Enhancement of neointima formation with tissue-type plasminogen activator. <i>Journal of Vascular Surgery</i> , <b>2001</b> , 33, 821-8	3.5	12
37	Plasmin and Matrix Metalloproteinases in Vascular Remodeling. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 86, 324-333	7	370
36	Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 3871-5	5.6	107
35	Retinoids induce the PAI-1 gene expression through tyrosine kinase-dependent pathways in vascular smooth muscle cells. <i>Journal of Cardiovascular Pharmacology</i> , <b>2002</b> , 39, 503-12	3.1	9
34	Increased fibrinogen, von Willebrand factor and tissue plasminogen activator levels in insulin resistant South Asian patients with ischaemic stroke. <i>Atherosclerosis</i> , <b>2002</b> , 163, 371-6	3.1	9
33	A new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis time. <i>BMC Biotechnology</i> , <b>2002</b> , 2, 8	3.5	25
32	Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 472-84	3.5	64
31	A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 2006-21	3.5	27

30	Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. <i>Pharmacotherapy</i> , <b>2005</b> , 25, 637-45	5.8	16
29	Role of thrombogenic factors in the development of atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2005</b> , 12, 1-8	4	45
28	A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. <i>Diabetes Research and Clinical Practice</i> , <b>2005</b> , 69, 5-13	7.4	70
27	Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2006</b> , 13, 47-52	2.9	2
26	Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2006</b> , 13, 227-31		107
25	Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. <i>Journal of International Medical Research</i> , <b>2006</b> , 34, 545-55	1.4	18
24	Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2007</b> , 14, 175-83		11
23	Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. <i>Internal Medicine</i> , <b>2007</b> , 46, 1837-46	1.1	20
22	The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity. <i>Blood</i> , <b>2007</b> , 109, 5286-92	2.2	25
21	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. <i>Diabetes and Metabolism</i> , <b>2007</b> , 33, 129-34	5.4	100
20	Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2007</b> , 14, 45-51		29
19	Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , <b>2008</b> , 24, 491-7	2.4	22
18	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 1973-83	2.5	33
17	Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2009</b> , 16, 698-704		10
16	Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 1239-47	4	22
15	Dysfunction of annexin A2 contributes to hyperglycaemia-induced loss of human endothelial cell surface fibrinolytic activity. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 1070-8	7	17
14	Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2020</b> , 40, 1479-1490	9.4	16
13	Arsenite induces tissue factor synthesis through Nrf2 activation in cultured human aortic smooth muscle cells. <i>Journal of Toxicological Sciences</i> , <b>2021</b> , 46, 187-192	1.9	

12	Arsenite Inhibits Tissue-Type Plasminogen Activator Synthesis through NRF2 Activation in Cultured Human Vascular Endothelial EA.hy926 Cells. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	0
11	Cardiopulmonary thromboembolism detected by Tc-99m MH-1 antifibrin antibody. <i>Clinical Nuclear Medicine</i> , <b>1997</b> , 22, 376-9	1.7	1
10	Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. <i>Circulation</i> , <b>1995</b> , 91, 1952-8	16.7	185
9	Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. <i>Journal of Clinical Investigation</i> , <b>1993</b> , 92, 2756-60	15.9	302
8	The Role of Hemostatic Factors in Atherosclerosis in Patients with Chronic Renal Disease. <i>Electronic Physician</i> , <b>2015</b> , 7, 1270-6	1.8	11
7	F. <b>2000</b> , 90-143		
6	Gender specifics of the association between blood fibrinolytic activity and cardiovascular disease or diabetes mellitus in a cohort of Muscovites aged 55 years or older. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , <b>2012</b> , 11, 52-58	0.9	
5	Cardiovascular Changes of the Perimenopause and Menopause. <b>1997</b> , 210-232		
4	Molecular Analysis of Vascular Development and Disorders. <i>Developments in Cardiovascular Medicine</i> , <b>1999</b> , 193-225		
3	Biological Effects of Targeted Gene Inactivation and Gene Transfer of the Coagulation and Fibrinolytic Systems in Mice. <b>1997</b> , 79-99		
2	Effects of Aerobic Fitness and Adiposity on Coagulation Biomarkers in Men vs. Women with Elevated Blood Pressure. <i>The European Journal of Cardiovascular Medicine</i> , <b>2012</b> , 2, 122-128		
1	Granulocyte Colony-Stimulating Factor Ameliorates Endothelial Activation and Thrombotic Diathesis Biomarkers in a Murine Model of Hind Limb Ischemia. <b>2022</b> , 10, 2303		0